An Open-Label Extension Study to Investigate the Long-Term Safety, and Tolerability of Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Valproic acid (Primary)
- Indications Partial epilepsies; Seizures
- Focus Adverse reactions
- Sponsors Cerebral Therapeutics
Most Recent Events
- 11 Mar 2024 Status changed from recruiting to discontinued.
- 14 Mar 2023 Planned End Date changed from 1 Oct 2024 to 1 Dec 2026.
- 14 Mar 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Dec 2026.